Immutep develops T-cell response-based immunotherapeutics against cancer and infectious diseases. |
   |
© 2002 Immutep, S.A.
|
Press Release
06/2008 - LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy
Immutep S.A. announced today the publication of research conducted by ...
11/2007 - IMP321 first results in metastatic breast cancer 
Immutep S.A announced positive interim results from a Phase I/II ...
09/2007 - IMP321’s potency as a new immunopotentiator in cancer patients 
Immutep Announces That ImmuFact® IMP321 Induces Activation of a Wide ...
09/2007 - Entering Phase I 
lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I ...
10/2006 - Entering Phase I 
lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I ...
|
||||||||